Search Results

You are looking at 71 - 80 of 127 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

less common cell types include papillary, chromophobe, and Bellini duct (collecting duct) tumors. Collecting duct carcinoma constitutes fewer than 1% of kidney cancer cases. Medullary renal carcinoma is a variant of collecting duct renal carcinoma and

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

that targets the hypoxia inducible factors (HIFs) for ubiquitin-mediated degradation. Mutation of the proto-oncogene MET, which codes for the hepatocyte growth factor receptor, is found in the hereditary form of type 1 papillary RCC and in a subset of

Full access

Stephanie L. Lee

. 2. Hay ID . Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma . J Surg Oncol 2006 ; 94 : 692 – 700 . 3. Verburg FA Dietlein M

Full access

Lainie Martin and Russell J. Schilder

. Eisen T Boshoff C Mak I . Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer 2000 ; 82 : 812 – 817 . 36. Abramson N Stokes PK Luke M . Ovarian and papillary

Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

markers for mOCs are more likely to be positive for CK7, CK20, and CEA, whereas only CK20 and CEA are likely to be positive for CRC. Histologically, mOCs are more likely to show a papillary growth pattern, with an expansile pattern of invasion. Metastatic

Full access

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini

. 11 Histologic features of OCCC are characterized by solid, papillary, and tubulocystic patterns. 12 Most OCCCs are presumed to arise from endometriotic cysts, 13 and key driver events involving HN-F1B overexpression and somatic ARID1A mutations

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

may require additional tissue samples include mucin-producing lesions, potential phyllodes tumor, papillary lesions, radial scars, or other histologies of concern to the pathologist. 77 , 83 , 84 , 90 This recommendation is supported by results of

Full access

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

, relative to the referent clear-cell histology, both chromophobe (HR, 0.4 at baseline to 0.5 at 96 months of event-free follow-up) and papillary histology (HR, from 0.8 to 0.6, respectively) were stable. Conversely, the CSM hazard was no more significant

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

the colon and lung, papillary thyroid cancer, melanoma, and hairy cell leukemia. 8 In BRAF V600E -mutated melanoma, combined BRAF and MEK inhibition has shown superiority to BRAF monotherapy and has proven to be an effective treatment for metastatic